We are live on ! Find out more
INSY

Insys Therapeutics, Inc.
INSY

Delisted

INSY was delisted on the 18th of June, 2019.

Back to rankings

71 hedge funds and large institutions have $151M invested in Insys Therapeutics, Inc. in 2013 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,100% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 3

214% more capital invested

Capital invested by funds: $48.1M → $151M (+$103M)

87% more funds holding

Funds holding: 38 → 71 (+33)

7% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 15

Holders
71
Holders Change
+33
Holders Change %
+86.84%
% of All Funds
2.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
36
Increased
16
Reduced
15
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$10M
2
Allianz Asset Management
Allianz Asset Management
Germany
+$6.41M
3
Invesco
Invesco
Georgia
+$6.09M
4
Renaissance Technologies
Renaissance Technologies
New York
+$3.88M
5
BIM
Bogle Investment Management
Massachusetts
+$3.2M

Top Sellers

Rank Fund Capital Flow
1
PI
Putnam Investments
Massachusetts
-$6.12M
2
JP Morgan Chase
JP Morgan Chase
New York
-$5.54M
3
RA
Royce & Associates
New York
-$5.02M
4
BC
Broadfin Capital
New York
-$4.15M
5
Wells Fargo
Wells Fargo
California
-$3.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
26
Dupont Capital Management
Delaware
$1.6M +$1.13M +137,652 New
Millennium Management
27
Millennium Management
New York
$1.57M +$1.11M +134,829 New
GC
28
Guggenheim Capital
Illinois
$1.5M +$1.05M +128,172 New
ARTA
29
A.R.T. Advisors
New York
$1.47M +$1.03M +126,027 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.44M +$663K +80,721 +189%
Geode Capital Management
31
Geode Capital Management
Massachusetts
$1.31M +$396K +48,210 +75%
Ameriprise
32
Ameriprise
Minnesota
$1.26M +$878K +106,962 +11,283%
Deutsche Bank
33
Deutsche Bank
Germany
$1.16M -$486K -59,205 -37%
GH
34
GAM Holding
Switzerland
$978K – – –
Wellington Management Group
35
Wellington Management Group
Massachusetts
$952K +$670K +81,600 New
SIM
36
Spark Investment Management
New York
$803K +$566K +69,000 New
EMG
37
Ellington Management Group
Connecticut
$637K +$448K +54,600 New
TCIM
38
TIAA CREF Investment Management
New York
$578K +$46.5K +5,670 +13%
CS
39
Credit Suisse
Switzerland
$568K +$400K +48,675 New
BIM
40
BlackRock Investment Management
Delaware
$504K +$30.6K +3,723 +9%
Two Sigma Investments
41
Two Sigma Investments
New York
$391K +$275K +33,552 New
OAM
42
Oberweis Asset Management
Illinois
$388K +$273K +33,300 New
SO
43
STRS Ohio
Ohio
$360K +$195K +23,700 +329%
Jacobs Levy Equity Management
44
Jacobs Levy Equity Management
New Jersey
$339K +$239K +29,100 New
Royal Bank of Canada
45
Royal Bank of Canada
Ontario, Canada
$332K +$234K +28,452 New
Acadian Asset Management
46
Acadian Asset Management
Massachusetts
$324K +$228K +27,813 New
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$316K +$4.93K +600 +2%
Citadel Advisors
48
Citadel Advisors
Florida
$311K +$219K +26,673 New
SCA
49
SAC Capital Advisors
Connecticut
$280K +$197K +23,991 New
Charles Schwab
50
Charles Schwab
California
$263K +$177K +21,600 New
1
2
3

INSY Hedge Fund Activity: Q3 2013 in Review

71 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q3 2013, worth a combined $151M — up 214% from $48.1M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new INSY positions and 3 closed out — a net gain of 33 holders — while 16 added to existing stakes and 15 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $10M. The largest seller was Putnam Investments, cutting an estimated $6.12M.

  • 71 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q3 2013, up from 38 in Q2 2013.
  • Funds reported $151M of Insys Therapeutics, Inc. stock for Q3 2013, up 214% quarter-over-quarter.
  • 36 funds opened new Insys Therapeutics, Inc. positions in Q3 2013 and 3 closed out, a net change of +33 holders.
  • The largest Insys Therapeutics, Inc. buyer in Q3 2013 was Consonance Capital Management, an estimated $10M added.
  • The largest Insys Therapeutics, Inc. seller in Q3 2013 was Putnam Investments, an estimated $6.12M sold.

Based on aggregated 13F filings for Q3 2013.